Imatinib Stada (Imatinib)

Imatinib acts on malignant cells driven by BCR‑ABL, c‑KIT or PDGFR tyrosine‑kinase pathways. It is indicated for several hematologic and solid‑tumor indications.

• Chronic myeloid leukemia (CML): suppresses the BCR‑ABL driven leukemic clone and restores normal hematopoiesis.
• Philadelphia chromosome‑positive acute lymphoblastic leukemia (Ph+ ALL): adds to remission rates by targeting the same fusion protein.
• Gastrointestinal stromal tumor (GIST): blocks c‑KIT signaling to reduce tumor growth and recurrence.
• Other KIT‑positive tumors: provides disease control where KIT activation drives malignancy.

• Imatinib selectively inhibits the ATP‑binding sites of BCR‑ABL, c‑KIT and platelet‑derived growth factor receptor (PDGFR) tyrosine kinases. By preventing phosphorylation of downstream substrates, it blocks proliferative and survival signaling pathways that are essential for the growth of malignant cells, leading to cell cycle arrest and apoptosis in responsive tumors.

Adverse reactions vary in frequency and severity. Most patients experience mild to moderate events, while a minority may develop serious complications.

Common Side Effects

• Nausea and vomiting: gastrointestinal upset occurring early in therapy.
• Edema: peripheral swelling, often of the ankles.
• Fatigue: generalized tiredness that may affect daily activities.
• Diarrhea: loose stools that can be self‑limiting.
• Muscle cramps or pain: especially in the lower limbs.
• Rash: mild skin erythema or pruritus.

Serious or Rare Side Effects

• Severe neutropenia or thrombocytopenia: marked reduction in blood cells requiring monitoring.
• Hepatotoxicity: elevated liver enzymes or jaundice.
• Cardiac failure or left ventricular dysfunction: rare but potentially life‑threatening.
• Pulmonary arterial hypertension: persistent dyspnea and elevated pulmonary pressures.
• Stevens‑Johnson syndrome or toxic epidermal necrolysis: severe skin reactions needing immediate discontinuation.

Patients should be evaluated for baseline organ function and monitored throughout therapy.

• Monitor blood counts: perform regular CBC to detect cytopenias.
• Assess liver function: check transaminases before initiation and periodically thereafter.
• Evaluate cardiac status: baseline echocardiogram in patients with pre‑existing heart disease.
• Avoid in known hypersensitivity: discontinue if severe allergic reaction occurs.
• Use caution in pregnancy: safety data are limited; risk‑benefit assessment required.
• Store at room temperature: keep in the original container, protect from moisture and light.

Imatinib is metabolized primarily by CYP3A4, making it susceptible to drug‑drug interactions.

Major Interactions (Avoid)

• Strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole): may increase plasma levels and toxicity.
• Potent CYP3A4 inducers (e.g., rifampin, carbamazepine): can lower exposure and reduce efficacy.
• Concomitant use with antacids containing aluminum or magnesium: may impair absorption.

Moderate Interactions (Monitor Closely)

• Warfarin: may enhance anticoagulant effect, requiring INR monitoring.
• Diuretics (e.g., furosemide): can increase risk of fluid retention and edema.
• QT‑prolonging agents (e.g., sotalol): may augment cardiac conduction abnormalities.
• Vaccines (live attenuated): immunosuppression could reduce vaccine efficacy.